Detailed price information for Satellos Bioscience Inc (MSCLF) from The Globe and Mail including charting and trades.

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS ® platform to develop in vivo gene editing therapies for high unmet need ...

One of the simplest, most over-studied organisms in the world is the C. elegans nematode. For 13 years, a project called ...

Phase 1a data shows SAT-3247 was safe and well tolerated in 72 healthy volunteers after both single and repeated administration ...

Women with ongoing urinary incontinence could avoid invasive bladder pressure tests, as new research shows that a range of ...

RNA cancer vaccines are at the forefront of next-generation cancer immunotherapy, showcasing significant potential.

Pulse Biosciences, Inc. (NASDAQ: PLSE) Q4 2024 Earnings Call Transcript March 27, 2025 Pulse Biosciences, Inc. beats earnings ...

Welcome to Plus Therapeutics fourth quarter and full-year 2024 results conference call. Before we begin, we want to advise you that over the course of the call, including any question-and-answer ...

Soquelitinib is well-positioned as a first-in-class oral therapy that selectively inhibits ITK to modulate and control parallel signaling ... data from 16 patients in Cohort 1 and 10 patients ...

BioAtla is extending its runway beyond key clinical readouts in 1H 2026 by restructuring and realigning resources, which ...

Philip Taylor; Investor Relations; Pulse Biosciences Inc. Paul Laviolette; Co-Chairman of the Board, President, Chief Executive Officer; Pulse Biosciences Inc. Jon S ...